Retatrutide, a new dual activator of the GLP-1 target and glucose-dependent released polypeptide (GIP) binding site , is showing promising outcomes in initial human studies. Current research https://bookmarksoflife.com/story7082748/retatrutide-emerging-studies-and-possible-therapeutic-roles